Figures & data
Table 1 Summary of cases with discrepant results when Sanger sequencing, real-time PCR with the TheraScreen® kit, pyrosequencing, chip array infiniti® assay, and 454 next-generation sequencing were used to detect KRAS mutations in formalin-fixed, paraffin-embedded samples
Table 2 Concordance, sensitivity, specificity, and accuracy of Sanger sequencing, real-time polymerase chain reaction with TheraScreen® kit, pyrosequencing, and chip array infiniti® assay measured using 454 next-generation sequencing as the reference method
Table 3 Statistical correlation between tumor cell enrichment (neoplastic to non-neoplastic cell ratio evaluated on histology sections) and quantification of KRAS mutation abundance according to Sanger sequencing, real-time polymerase chain reaction with TheraScreen® kit, pyrosequencing, chip array infiniti® assay, and 454 next-generation sequencing